Nektar Therapeutics (OQ:NKTR)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 455 Mission Bay Boulevard South
SAN FRANCISCO CA 94158
Tel: 1-628-8950661
Website: https://www.nektar.com
IR: See website
<
Key People
Howard W. Robin
President, Chief Executive Officer, Director
Sandra A. Gardiner
Interim Chief Financial Officer
Mark A. Wilson
Senior Vice President, Chief Legal Officer
Mary Tagliaferri
Chief Medical Officer
Jonathan Zalevsky
Chief Research and Development Officer
 
Business Overview
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body's immune response to fight cancer. Its pipeline includes NKTR-255, Rezpegaldesleukin (REZPEG) and NKTR-0165. NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body's innate and adaptive immunity. Its Rezpegaldesleukin pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. Rezpegaldesleukin is being developed as a self-administered injection.
Financial Overview
For the fiscal year ended 31 December 2023, Nektar Therapeutics revenues decreased 2% to $90.1M. Net loss decreased 25% to $276.1M. Revenues reflect Rest of world segment decrease of 4% to $78.6M. Lower net loss reflects Research and development - Balancing val decrease of 47% to $100.3M (expense), Restructuring, impairment and other decrease of 77% to $15.3M (expense).
Employees: 137 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $90.12M as of Dec 31, 2023
EBITDA (TTM): -$126.11M as of Dec 31, 2023
Net annual income (TTM): -$276.06M as of Dec 31, 2023
Free cash flow (TTM): -$193.47M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 183,617,817 as of Feb 27, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.